NIAID issues amendment to antiviral, antibacterial treatment solication

The National Institutes of Allergy and Infectious Diseases (NIAID) released an amendment on Wednesday to its solicitation of proposals for therapeutic products designed to relieve bottlenecks in its ability to fight emerging infectious pathogens.

NIAID clarified the proposal it originally issued in June and is accepting questions about the solicitation through July 16.

NIAID plans to award between three and five contracts in fiscal year 2015 to advance promising lead therapeutics to the clinical drug stage at a total of $4 million. Drugs that have already been clinically tested do not meet the requirement of NIAID's solicitation.

The proposal applies to broad-spectrum anti-viral treatments against diseases in NIAID categories A, B and C viral threat agents. The drugs must also treat at least ebola virus, Marburg virus, variola major, dengue virus, chikungunya virus or influenza.

The NIAID solicitation also applies to anti-bacterial treatments for Bacillus anthracis, Francisella tularensis, Yersinia pestis, Burkholderia pseudomallei, B. mallei, and Rickettsia prowazekii.

Nonprofits are allowed to submit proposals under the NIAID solicitation.

The number of awards under the NIAID request will be determined following peer review, negotiation and allocation of funds.

Proposals that do not acknowledge receipt of the July amendment may be rejected. The proposal due date is Aug. 13 of this year.